Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Marginal Zone B-cell lymphoma

Written2001-07Antonio Cuneo, Gianluigi Castoldi
Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy
Updated2005-12Antonio Cuneo, Gianluigi Castoldi
Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9699/3 Extranodal marginal zone lymphoma of mucosa- associated lymphoid tissue (MALT lymphoma); Nodal marginal zone lymphoma; Paediatric nodal marginal zone lymphoma
Atlas_Id 2078

Clinics and Pathology

Disease Marginal zone B-cell lymphoma (MZBCL), including three distinct clinicopathological forms (Harris et al, 1999), namely:
  • 1- extra-nodal MZBCL of mucosa-associated lymphoid tissue ( MALT) type,
  • 2- splenic MZBCL, corresponding to splenic lymphoma with villous lymphocytes (SLVL)
  • 3- nodal MZBCL
  • Phenotype / cell stem origin The morphologic and phenotypic characteristics of malignant cells correspond to those of lymphocytes belonging to the marginal zone, harbouring hypermutated IgV genes with the following immunophenotype:
    pan-B+; CD5-/+; CD10-; CD23-; CD11c+/-; cyIg +(40% of the cells), sIgM+ bright; sIgD-
    Epidemiology The global incidence of MZBCL in western countries is approximately 10% of all non Hodgkin lymphomas (NHL) diagnosed by histologic examination
    Clinics
  • Extra-nodal MZBCL of MALT type (7% of all NHL) is an indolent disease involving most often the stomach, where it usually follows chronic gastritis due to Helicobacter pylori (HP) infection. The disease may also localize in the lung, the thyroid the salivary gland and in the orbit, where an association was documented with Chlamydia Psittaci infection.
  • Splenic MZBCL (1% of all NHL on histologic samples) usually, though not invariably, presents splenomegaly associated circulating villous lymphocytes and BM involvement. It runs an indolent course.
  • Nodal MZBCL (2% of al NHL) is a low-grade lymphoma, frequently presenting with advanced-stage disease, but not with large masses. Early relapse after chemotherapy may be observed in some patients and survival is shorter that in MZBCL of MALT type.
  • All subsets may transform into a high grade lymphoma
  • Pathology The tumour consists of a cytologically heterogeneous infiltrate including centrocyte-like cells, monocytoid B-cells small lymphocytes and plasma cells. Large cells and/or blast-like cells may be present. In epithelial tissues (i.e. stomach) typical lymphoepithelial lesions are characteristically seen. In the spleen, involvement of the mantle zone and marginal zone of the white pulp occur, usually centered around a residual germinal centre. The red pulp is usually involved.
    Treatment
  • Low grade MALT with limited disease involving the stomach is usually HP+ and respond to eradication of the HP infection. Cases presenting at a more advanced stage or with transformation into high grade lymphoma require single-agent or multi-agent chemotherapy.
  • Rituximab (anti-CD20 monoclonal antibody) is an effective treatment. Gastrectomy is indicated in non-responding patients.
  • Splenic MZBCL and nodal MZBCL are treated using various forms of chemotherapy depending on the disease stage and patient's conditions. Splenectomy is an option for splenic MZBCL
  • Prognosis The patients usually have prolonged survival, as in other indolent lymphomas, but some cases may feature an aggressive disease.

    Cytogenetics

    Cytogenetics Morphological
  • The most common anomalies in extra-nodal MZBCL of MALT type include:
  • the t(11;18)(q21;q21) / API2 - MLT fusion, having a 20-50% incidence. The translocation is associated with low-grade MALT lymphoma of the stomach and of the lung. Importantly, this translocation was associated with resistance to HP eradication therapy.
  • the translocation t(14;18)(q32;q21)/IgH-MLT1 fusion, leading to enhanced MLT1 expression may occur in 10-20% of all MALT lymphomas. It is associated with MALT lymphoma of the liver, skin, ocular adnexa, lung and salivary gland. It was not found in MALT lymphomas of the stomach, intestine, thyroid, or breast
  • The translocation t(1;14)(p22;q32)and/or the corresponding deregulation or rearrangement of BCL10 at 1p22 is another recurrent chromosome aberration in a minority of cases (6% by molecular genetics, including cases with BCL10 mutations and small deletions not detectable by cytogenetics) and it appears to be more frequent in high grade-MALT than in low grade MALT lymphoma.
  • the t(3;14)/IgH-FOXP1 fusion may occur in 10% of all MALT lymphomas. It is associated with MALT lymphoma of the orbit, of the thyroid and skin, whereas it was not found in MALT lymphoma of the stomach, of the salivary gland and in other forms of MZBCL
  • Trisomy 3 and trisomy 18 were reported in low-grade as well as high-grade MALT lymphoma. FISH studies found a 20-60% incidence for + 3, the difference being possibly accounted for by the variable sensitivity of methods adopted in different studies and by heterogeneity of patient populations. At the present time, there is no evidence that +3 plays an important role in disease progression. Trisomy 18 was observed more frequently in high grade MALT than in low grade MALT lymphomas.
  • The most common anomalies in splenic MZBCL include:
  • 7q deletions or unbalanced 7q translocations, usually involving a relatively large segment, centred around the 7q22-q32 region. The incidence is 10-30%, but as many as 40% of the cases may harbour a sub-microscopic deletion of this region. The commonly deleted segment spans a region between 7q32.1 to 7q32-3.
  • total or partial trisomy 3, involving the 3q21-23 and 3q25-29 chromosome regions. The incidence of +3q falls in the 30-50% range
  • total or partial trisomy 12, found in 20-30% of the cases
  • 17p- involving the p53 gene, found in 10-30% of the cases. This aberration is associated with a more aggressive clinical course.
  • A recurrent translocation t(11;14)(p11;q32) was found in a minority of cases featuring a relatively aggressive disease with PB involvement by a blast-like cell component.
  • The classical t(11;14)(q13;q32) was found in some cases of splenic lymphoma with villous lymphocytes (Oscier et al, 1993), but more recent studies did not detect this translocation in histologically documented splenic MZBCL.
  • Nodal MZBCL
  • At the present time there is insufficient data to establish whether nodal MZBCL has a distinct cytogenetic profile. Trisomy 12 may be more frequent in nodal MZBCL, but there is evidence that this disease subset may share clinicopathologic and cytogenetic features with other forms of MZBCL.
  • In the 3 principal clinicopathological subsets of MZBCL, BCL6 rearrangements were documented to occur in a minority of cases, especially in the presence of a high-grade component.
  • Cytogenetics Molecular

    Genes involved and Proteins

    Note Oncogenesis:
  • MALT1 overexpression and API2-MALT fusion confer constitutional NFkB activity. This, in turn, leads to enhanced proliferation and resistance to apoptosis by B lymphocytes.
  • BCL10 has a pro-apoptotic action on cell lines. However, it functions in conjunction with intracellular proteins (Carma1 and MALT1), producing the ubiquitination of NFkB inhibitor, leading to NFkB activation. These findings, along with the documented role of BCL10 in promoting survival of antigen-stimulated lymphocytes, suggest that IgH/BCL10 translocation may contribute to lymphomagenesis by enhancing BCL10 function.
  • P53 is a key tumour suppressor gene having an established role in disease progression in a number of hematologic and extra-hematologic neoplasias, including MZBCL.
  • Bibliography

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.
    Blood. 1997 ; 89 (11) : 3909-3918.
    PMID 9166827
     
    Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection.
    Alpen B, Neubauer A, Dierlamm J, Marynen P, Thiede C, Bayerdörfer E, Stolte M
    Blood. 2000 ; 95 (12) : 4014-4015.
    PMID 10939796
     
    Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases.
    Cuneo A, Bigoni R, Roberti MG, Milani R, Agostini P, Cavazzini F, Minotto C, De Angeli C, Bardi A, Tammiso E, Negrini M, Cavazzini P, Castoldi G
    Haematologica. 2001 ; 86 (1) : 64-70.
    PMID 11146573
     
    Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes.
    Dierlamm J, Baens M, Stefanova-Ouzounova M, Hinz K, Wlodarska I, Maes B, Steyls A, Driessen A, Verhoef G, Gaulard P, Hagemeijer A, Hossfeld DK, De Wolf-Peeters C, Marynen P
    Blood. 2000 ; 96 (6) : 2215-2218.
    PMID 10979968
     
    BCL10 gene mutation in lymphoma.
    Du MQ, Peng H, Liu H, Hamoudi RA, Diss TC, Willis TG, Ye H, Dogan A, Wotherspoon AC, Dyer MJ, Isaacson PG
    Blood. 2000 ; 95 (12) : 3885-3890.
    PMID 10845924
     
    Frequent mutation of bcl-6 proto-oncogene in high grade, but not low grade, MALT lymphomas of the gastrointestinal tract.
    Gaidano G, Capello D, Gloghini A, Fassone L, Vivenza D, Ariatti C, Migliazza A, Saglio G, Carbone A
    Haematologica. 1999 ; 84 (7) : 582-588.
    PMID 10406897
     
    p53 abnormalities in splenic lymphoma with villous lymphocytes.
    Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D
    Blood. 2001 ; 97 (11) : 3552-3558.
    PMID 11369650
     
    World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
    Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 ; 17 (12) : 3835-3849.
    PMID 10577857
     
    Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.
    Hernández JM, García JL, Gutiérrez NC, Mollejo M, Martínez-Climent JA, Flores T, González MB, Piris MA, San Miguel JF
    The American journal of pathology. 2001 ; 158 (5) : 1843-1850.
    PMID 11337382
     
    MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.
    Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM, Schwaller J
    Blood. 2005 ; 105 (7) : 2891-2899.
    PMID 15598810
     
    Gastric low-grade MALT lymphoma, high-grade MALT lymphoma and diffuse large B cell lymphoma show different frequencies of trisomy.
    Hoeve MA, Gisbertz IA, Schouten HC, Schuuring E, Bot FJ, Hermans J, Hopman A, Kluin PM, Arends JW, van Krieken JH
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999 ; 13 (5) : 799-807.
    PMID 10374886
     
    p53 in hematologic malignancies.
    Imamura J, Miyoshi I, Koeffler HP
    Blood. 1994 ; 84 (8) : 2412-2421.
    PMID 7919360
     
    Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy.
    Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, Hamoudi RA, Diss TC, Dogan A, Megraud F, Rambaud JC, Du MQ, Isaacson PG
    Lancet. 2001 ; 357 (9249) : 39-40.
    PMID 11197361
     
    Non Hodgkin's lymphoma: Molecular features of non Hodgkin's lymphoma.
    Macintyre E, Willerford D, Morris AW
    Congress of the American Society of Hematology..
     
    The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type.
    Maes B, Baens M, Marynen P, De Wolf-Peeters C
    Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2000 ; 11 (5) : 521-526.
    PMID 10907943
     
    Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
    Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 ; 23 (9) : 1979-1983.
    PMID 15668468
     
    7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma.
    Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martínez P, Piris MA
    The American journal of pathology. 1999 ; 154 (5) : 1583-1589.
    PMID 10329610
     
    Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.
    Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Müller-Hermelink HK, Ullrich FA, Weisenburger DD
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 ; 17 (8) : 2486-2492.
    PMID 10561313
     
    Cytogenetic studies in splenic lymphoma with villous lymphocytes.
    Oscier DG, Matutes E, Gardiner A, Glide S, Mould S, Brito-Babapulle V, Ellis J, Catovsky D
    British journal of haematology. 1993 ; 85 (3) : 487-491.
    PMID 8136270
     
    The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type.
    Ott G, Katzenberger T, Greiner A, Kalla J, Rosenwald A, Heinrich U, Ott MM, Müller-Hermelink HK
    Cancer research. 1997 ; 57 (18) : 3944-3948.
    PMID 9307277
     
    Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1.
    Remstein ED, Kurtin PJ, Einerson RR, Paternoster SF, Dewald GW
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004 ; 18 (1) : 156-160.
    PMID 14574335
     
    Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q.
    Solé F, Salido M, Espinet B, Garcia JL, Martinez Climent JA, Granada I, Hernández JM, Benet I, Piris MA, Mollejo M, Martinez P, Vallespí T, Domingo A, Serrano S, Woessner S, Florensa L
    Haematologica. 2001 ; 86 (1) : 71-77.
    PMID 11146574
     
    T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.
    Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (4) : 652-658.
    PMID 15703784
     
    Bcl10 can promote survival of antigen-stimulated B lymphocytes.
    Tian MT, Gonzalez G, Scheer B, DeFranco AL
    Blood. 2005 ; 106 (6) : 2105-2112.
    PMID 15878976
     
    B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours.
    Zucca E, Roggero E, Pileri S
    British journal of haematology. 1998 ; 100 (1) : 3-14.
    PMID 9450784
     

    Citation

    This paper should be referenced as such :
    Cuneo, A ; Castoldi, GL
    Marginal zone B-cell lymphoma
    Atlas Genet Cytogenet Oncol Haematol. 2006;10(3):180-183.
    Free journal version : [ pdf ]   [ DOI ]
    On line version : http://AtlasGeneticsOncology.org/Anomalies/MarginalZoneBID2078.html
    History of this paper:
    Cuneo, A ; Castoldi, GL. Marginal zone B-cell lymphoma. Atlas Genet Cytogenet Oncol Haematol. 2001;5(3):204-206.
    http://documents.irevues.inist.fr/bitstream/handle/2042/37763/07-2001-MarginalZoneBID2078.pdf


    Other genes implicated (Data extracted from papers in the Atlas) [ 8 ]

    Genes AKT1 BIRC3 CCR1 FOXP1 IGH MALT1 SYK TNFAIP3

    External links

    COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
    arrayMapTopo ( C42) Morph ( 9699/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
     
     
    Disease databaseMarginal Zone B-cell lymphoma
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed
    All articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Tue Mar 14 13:54:05 CET 2017


    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.